Sunday 18 October 2026 Export AGEN’s income statement to Excel — free account

Agenus Inc.

Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.

6.04 0.64 −9.58%

Follow AGEN

Alert me

Market cap: $301.7M
P/E: 2.3×
Fwd P/E: 4.1×
Dividend yield: —
F-score: 4/9
Altman Z: −14.16
Beneish M: 12.57
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.48%

Capital & Financial Ratios $m

Market Cap 301.68

Revenue 132.69

Net Income 91.94

Free Cash Flow (98.16)

Net Debt 11.33

Current Ratio 0.34

Debt/Equity (0.15)

P/E ratio 2.28

Fwd P/E 4.11

P/S ratio 1.88

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 114.08%

Next Y EPS Growth (325.23%)

Next Y revenue growth 9.64%

Next 5Y EPS Growth 32.54%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 24.92%

10-year low 10-year high

EV/Sales against its own 10 years 35.02%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	76	40	3	19
Receivables	26	0	7	55
Inventory	—	—	—	—
Other	2	2	123	2
	112	46	133	79

	2023	2024	2025	Q'26
Payables	61	61	83	59
ST’ Debt	0	3	45	30
Other	146	120	161	114
	256	221	323	232

Compound Annual Growth %

	10y	5y	3y
Sales	16.49%	5.31%	5.22%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	34	35	—	—	—
’25	24	26	30	34	114
’24	28	24	25	27	103
’23	23	25	24	84	156
’22	26	21	23	28	98
’21	12	11	253	20	296
’20	15	27	15	31	88

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(36)	(31)	—	—	—
’25	(26)	(20)	(15)	(17)	(77)
’24	(38)	(38)	(53)	(29)	(158)
’23	(59)	(60)	(65)	(40)	(224)
’22	(52)	(43)	(32)	(47)	(175)
’21	(43)	(56)	131	(23)	10
’20	(35)	(37)	(32)	(36)	(139)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(36)	(31)	—	—	—
’25	(26)	(20)	(15)	(17)	(77)
’24	(38)	(39)	(53)	(29)	(159)
’23	(60)	(64)	(69)	(38)	(231)
’22	(57)	(52)	(48)	(50)	(206)
’21	(43)	(58)	109	(26)	(18)
’20	(35)	(38)	(32)	(36)	(143)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.02	(0.01)	—	—	—
’25	(1.03)	(1.00)	1.94	(0.37)	0.00
’24	(3.04)	(2.52)	(3.08)	(2.04)	(10.59)
’23	(4.40)	(4.00)	(3.20)	(2.60)	(13.80)
’22	(3.80)	(3.40)	(3.80)	(4.80)	(15.60)
’21	(5.40)	(7.40)	14.40	(5.20)	(2.20)
’20	(6.20)	(5.60)	(5.60)	(4.00)	(21.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	51.23	62.81	30.23	41.81	35.72	49.07	24.53	12.20	2.50	1.38	Analyst estimates 2026–2028 Powerpack
	High	147.01	106.97	121.49	89.70	110.50	133.27	68.50	60.26	19.69	7.34
People
People	Employees	255	255	294	328	359	441	533	389	316	81
	Revenue/emp, $m	0.09	0.17	0.13	0.46	0.25	0.67	0.18	0.40	0.33	1.41
Income, $m
Income, $m	Revenue	23	43	37	150	88	296	98	156	103	114
	Gross margin, %	100.00	100.00	100.00	100.00	97.34	98.83	89.22	98.01	99.53	99.11
	EBT	(127)	(121)	(162)	(112)	(183)	(29)	(231)	(257)	(232)	(3)
	EBT margin, %	(562.59)	(281.48)	(440.53)	(74.35)	(207.43)	(9.72)	(235.31)	(164.69)	(224.50)	(2.70)
	Net income	(127)	(121)	(162)	(112)	(183)	(29)	(231)	(257)	(232)	(3)
	Depreciation	5	6	6	7	7	7	7	14	13	10
Per share, $
Per share, $	Revenue	5.19	8.71	6.64	22.23	10.22	25.83	6.96	8.74	4.82	3.84
	Earnings	(29.20)	(24.60)	(28.80)	(16.00)	(21.00)	(2.20)	(15.60)	(13.80)	(10.59)	0.00
	Cash flow	(18.37)	(19.15)	(23.67)	(2.77)	(16.13)	0.89	(12.45)	(12.53)	(7.37)	(2.60)
	Capex	(2.88)	(0.61)	(0.65)	(0.69)	(0.40)	(2.46)	(2.21)	(0.37)	(0.03)	0.01
	Free cash flow	(21.24)	(19.76)	(24.32)	(3.46)	(16.53)	(1.57)	(14.65)	(12.90)	(7.40)	(2.58)
	Book value	(8.99)	(15.41)	(31.51)	(34.28)	(24.52)	4.19	(3.90)	(8.29)	(14.27)	(9.34)
	Shares, m	4	5	6	7	9	11	14	18	21	30
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	15.75	7.97	7.03	3.59	6.11	2.45	6.77	1.83	0.57	0.82
	P/B	0.00	0.00	0.00	0.00	0.00	15.10	0.00	0.00	0.00	0.00
	EV/Sales	18.15	10.37	5.95	3.27	5.20	1.45	4.93	1.43	0.50	1.39
	EV/FCF	(4.43)	(4.57)	(1.63)	(21.05)	(3.21)	(23.87)	(2.34)	(0.97)	(0.32)	(2.06)
Cash, $m
Cash, $m	Operating cash flow	(80)	(94)	(131)	(19)	(139)	10	(175)	(224)	(158)	(77)
	Capex	(13)	(3)	(4)	(5)	(3)	(28)	(31)	(7)	(1)	0
	Free cash flow	(92)	(97)	(135)	(23)	(143)	(18)	(206)	(231)	(159)	(77)
Balance, $m
Balance, $m	Working capital	50	17	7	(36)	(16)	175	24	(143)	(176)	(190)
	Total debt	131	163	13	14	20	14	13	13	33	45
	Net debt	54	103	(40)	(48)	(80)	(293)	(180)	(63)	(7)	42
	Shareholders’ equity	(39)	(76)	(175)	(231)	(211)	48	(55)	(148)	(306)	(278)
Returns, %
Returns, %	ROA	(63.72)	(81.86)	(116.37)	(73.95)	(97.94)	(7.09)	(50.09)	(67.62)	(84.20)	(0.04)
	ROIC	(444.11)	(240.08)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(805.04)	210.36	127.73	53.15	81.80	29.51	6,300.19	242.00	100.01	0.03

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CYPH Cypherpunk Technologies Inc.	$325.5M	4.4×	— (loss-making)	0.00%	n/m	+15.53% (above 0%: growing)	0.00%	0.00%	Compare
ARCT Arcturus Therapeutics Holdings Inc.	$320.3M	— (loss-making)	— (loss-making)	−89.54% (below 0%: shrinking)	n/m	−245.65% (below 0%: shrinking)	100.00%	(863.30%)	Compare
AGEN Agenus Inc.	$301.7M	2.3×	4.1×	+34.36% (above 0%: growing)	n/m	−55.25% (below 0%: shrinking)	100.00%	32.72%
CTNM Contineum Therapeutics, Inc.	$297.2M	— (loss-making)	—	—	n/m	+26.73% (above 0%: growing)	100.00%	0.00%	Compare
ARTV Artiva Biotherapeutics, Inc.	$296.3M	— (loss-making)	— (loss-making)	—	n/m	+13.60% (above 0%: growing)	100.00%	0.00%	Compare
BNTC Benitec Biopharma Limited	$295.1M	— (loss-making)	— (loss-making)	−85.42% (below 0%: shrinking)	n/m	+38.90% (above 0%: growing)	0.00%	0.00%	Compare
SRZN Surrozen, Inc.	$294.7M	— (loss-making)	— (loss-making)	+408.65% (above 0%: growing)	n/m	−21.25% (below 0%: shrinking)	100.00%	(207.40%)	Compare
FULC Fulcrum Therapeutics, Inc.	$280.0M	— (loss-making)	— (loss-making)	+27,018.64% (above 0%: growing)	n/m	−13.05% (below 0%: shrinking)	100.00%	0.00%	Compare
OCGN Ocugen, Inc.	$275.9M	— (loss-making)	— (loss-making)	+8.38% (above 0%: growing)	n/m	−13.42% (below 0%: shrinking)	100.00%	(1,105.11%)	Compare
Median of peers	$295.7M	—	—	+4.19%	—	+0.28%	100.00%	0.00%

All 614 Biotechnology stocks →

Agenus Inc. (AGEN) key facts

Strength: Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
Agenus Inc. (AGEN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AGEN traded at $6.04, a market capitalization of $301.7 million.
Return on equity was 0.03% and debt-to-equity -0.15.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −14.16 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.